Share This Author
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
It is shown that conditional inactivation of Trp53 in the mouse prostate fails to produce a tumour phenotype, whereas complete Pten inactivation in the prostate triggers non-lethal invasive prostate cancer after long latency, and support a model for cooperative tumour suppression in which p53 is an essential failsafe protein of Pten-deficient tumours.
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Identification of a tumour suppressor network opposing nuclear Akt function
- L. Trotman, A. Alimonti, P. Scaglioni, J. Koutcher, C. Cordon-Cardo, P. Pandolfi
- 25 May 2006
It is demonstrated that Pml orchestrates a nuclear tumour suppressor network for inactivation of nuclear pAkt, and thus highlights the importance of AKT compartmentalization in human cancer pathogenesis and treatment.
Pten Dose Dictates Cancer Progression in the Prostate
The results provide conclusive genetic support for the notion that PTEN is haploinsufficient in tumor suppression and that its dose is a key determinant in cancer progression.
Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality.
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
Surprisingly, it was found that only the combination of both agents together induced dramatic shrinkage of erlotinib-resistant tumors harboring the T790M mutation, because together they efficiently depleted both phosphorylated and total EGFR.
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
- A. Lockhart, M. Rothenberg, W. Tew
- Medicine, BiologyJournal of clinical oncology : official journal…
- 10 January 2010
VEGF Trap was well tolerated at the dose levels tested and pharmacodynamic and pharmacokinetic markers were indicative of VEGF blockade, and the recommended phase II dose is 4 mg/kg every 2 weeks.
Dose-Dependent Effects of Platelet-Derived Growth Factor-B on Glial Tumorigenesis
- A. Shih, C. Dai, Xiaoyi Hu, M. Rosenblum, J. Koutcher, E. Holland
- Biology, MedicineCancer Research
- 15 July 2004
The data show that PDGFR signaling quantitatively regulates tumor grade and is required to sustain high-grade oligodendrogliomas.
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy.
MR spectroscopic imaging measurement of prostate tumor (Cho + Cr)/Cit and tumor volume correlate with pathologic Gleason score and has potential in noninvasive assessment of prostate cancer aggressiveness.